OBJECTIVE: Aniridic keratopathy is a major cause of vision loss in patients with aniridia. Penetrating keratoplasty has been proven ineffective for the long-term treatment of this disorder because it does not address the stem cell deficiency that is the primary etiologic factor. We evaluated the role of keratolimbal allograft (KLAL), a stem cell transplantation technique, for the treatment of patients with aniridic keratopathy. DESIGN: Retrospective noncomparative interventional case series. PARTICIPANTS: Thirty-one eyes of 23 patients with aniridic keratopathy. INTERVENTION: KLAL. MAIN OUTCOME MEASURES: Ocular surface stability, visual acuity, and success of subsequent penetrating or lamellar keratoplasty. RESULTS: Thirty-one eyes of 23 patients were treated with KLAL and followed up for 12 to 117 months (mean, 35.7 months). Twenty-three eyes (74.2%) achieved a stable ocular surface. Overall, the mean visual acuity improved from 20/1000 to 20/165. Twenty eyes (64.5%) underwent subsequent penetrating keratoplasty. Fourteen corneal transplant grafts (70.0%) were successful, and six (30.0%) failed. Nineteen (90.5%) of 21 eyes receiving systemic immunosuppression obtained a stable ocular surface, whereas only 4 (40.0%) of 10 eyes not receiving systemic immunosuppression achieved ocular surface stability (P < 0.01). CONCLUSIONS: KLAL is effective in treating aniridic keratopathy. Patients receiving systemic immunosuppression have a greater likelihood of achieving ocular surface stability and improved visual acuity compared with those who receive only topical immunosuppression.
OBJECTIVE:Aniridic keratopathy is a major cause of vision loss in patients with aniridia. Penetrating keratoplasty has been proven ineffective for the long-term treatment of this disorder because it does not address the stem cell deficiency that is the primary etiologic factor. We evaluated the role of keratolimbal allograft (KLAL), a stem cell transplantation technique, for the treatment of patients with aniridic keratopathy. DESIGN: Retrospective noncomparative interventional case series. PARTICIPANTS: Thirty-one eyes of 23 patients with aniridic keratopathy. INTERVENTION: KLAL. MAIN OUTCOME MEASURES: Ocular surface stability, visual acuity, and success of subsequent penetrating or lamellar keratoplasty. RESULTS: Thirty-one eyes of 23 patients were treated with KLAL and followed up for 12 to 117 months (mean, 35.7 months). Twenty-three eyes (74.2%) achieved a stable ocular surface. Overall, the mean visual acuity improved from 20/1000 to 20/165. Twenty eyes (64.5%) underwent subsequent penetrating keratoplasty. Fourteen corneal transplant grafts (70.0%) were successful, and six (30.0%) failed. Nineteen (90.5%) of 21 eyes receiving systemic immunosuppression obtained a stable ocular surface, whereas only 4 (40.0%) of 10 eyes not receiving systemic immunosuppression achieved ocular surface stability (P < 0.01). CONCLUSIONS: KLAL is effective in treating aniridic keratopathy. Patients receiving systemic immunosuppression have a greater likelihood of achieving ocular surface stability and improved visual acuity compared with those who receive only topical immunosuppression.
Authors: Takuya Nakayama; Marilyn Fisher; Keisuke Nakajima; Akinleye O Odeleye; Keith B Zimmerman; Margaret B Fish; Yoshio Yaoita; Jena L Chojnowski; James D Lauderdale; Peter A Netland; Robert M Grainger Journal: Dev Biol Date: 2015-02-25 Impact factor: 3.582
Authors: Caroline O Adeoti; Adebimpe A Afolabi; Adeyinka A Afolabi; Adeyinka O Ashaye; Adebimpe O Ashaye; Adenike O Adeoye Journal: Clin Ophthalmol Date: 2010-10-05